JANSSEN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN, and what generic alternatives to JANSSEN drugs are available?
JANSSEN has seventy-nine approved drugs.
There are seventy-nine US patents protecting JANSSEN drugs.
There are two thousand two hundred and sixty-seven patent family members on JANSSEN drugs in seventy-two countries and four hundred and forty-three supplementary protection certificates in twenty countries.
Summary for JANSSEN
| International Patents: | 2267 |
| US Patents: | 79 |
| Tradenames: | 75 |
| Ingredients: | 51 |
| NDAs: | 79 |
| Patent Litigation for JANSSEN: | See patent lawsuits for JANSSEN |
| PTAB Cases with JANSSEN as patent owner: | See PTAB cases with JANSSEN as patent owner |
Drugs and US Patents for JANSSEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | DURAGESIC-50 | fentanyl | FILM, EXTENDED RELEASE;TRANSDERMAL | 019813-003 | Aug 7, 1990 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-002 | Apr 12, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-004 | Mar 18, 2021 | RX | Yes | No | RE43728 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Janssen Pharms | ORTHO CYCLEN-28 | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 019653-002 | Dec 29, 1989 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-001 | Jul 1, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-003 | Mar 18, 2021 | RX | Yes | No | 10,220,023 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JANSSEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Pharms | LEVAQUIN | levofloxacin | INJECTABLE;INJECTION | 020635-004 | Dec 20, 1996 | 5,053,407*PED | ⤷ Sign Up |
| Janssen R And D | INTELENCE | etravirine | TABLET;ORAL | 022187-001 | Jan 18, 2008 | 7,887,845*PED | ⤷ Sign Up |
| Janssen Pharms | CONCERTA | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021121-003 | Dec 8, 2000 | 5,082,668*PED | ⤷ Sign Up |
| Janssen Pharms | INVEGA TRINZA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-002 | May 18, 2015 | 6,077,843*PED | ⤷ Sign Up |
| Janssen Pharms | DURAGESIC-75 | fentanyl | FILM, EXTENDED RELEASE;TRANSDERMAL | 019813-002 | Aug 7, 1990 | 4,144,317 | ⤷ Sign Up |
| Janssen Pharms | RISPERDAL | risperidone | TABLET, ORALLY DISINTEGRATING;ORAL | 021444-004 | Dec 23, 2004 | 5,648,093*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Injectable Suspension | 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL | ➤ Subscribe | 2017-11-21 |
| ➤ Subscribe | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
| ➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2017-08-23 |
| ➤ Subscribe | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | ➤ Subscribe | 2017-03-29 |
| ➤ Subscribe | Extended-release Capsules | 16 mg and 24 mg | ➤ Subscribe | 2006-03-11 |
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
| ➤ Subscribe | Tablets | 25 mg, 100 mg and 200 mg | ➤ Subscribe | 2001-12-26 |
| ➤ Subscribe | Capsules | 15 mg and 25 mg | ➤ Subscribe | 2005-09-07 |
| ➤ Subscribe | Tablets | 10 mg, 15 mg, and 20 mg | ➤ Subscribe | 2015-07-01 |
| ➤ Subscribe | Tablets | 4 mg, 8 mg and 12 mg | ➤ Subscribe | 2005-02-28 |
| ➤ Subscribe | Orally Disintegrating Tablets | 3 mg and 4 mg | ➤ Subscribe | 2005-03-23 |
| ➤ Subscribe | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
| ➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2015-04-28 |
| ➤ Subscribe | Tablets | 6.25 mg and 12.5 mg | ➤ Subscribe | 2005-12-08 |
| ➤ Subscribe | Extended-release Capsules | 8 mg | ➤ Subscribe | 2006-03-02 |
| ➤ Subscribe | Tablets | 100 mg and 300 mg | ➤ Subscribe | 2017-03-29 |
| ➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2013-05-03 |
| ➤ Subscribe | Tablets | 50 mg | ➤ Subscribe | 2005-09-08 |
| ➤ Subscribe | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ➤ Subscribe | 2007-03-22 |
| ➤ Subscribe | Oral Solution | 25 mg/mL | ➤ Subscribe | 2009-07-30 |
| ➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg | ➤ Subscribe | 2005-04-11 |
International Patents for JANSSEN Drugs
Supplementary Protection Certificates for JANSSEN Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1663240 | CA 2015 00055 | Denmark | ⤷ Sign Up | PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER EN TERAPEUTISK AEKVIVALENT FORM DERAF, SOM ER BESKYTTET AF GRUNDPATENTET, SASOM ET FARMECEUTISK ACCEPTABELT SALT AF RILPIVIRIN, HERUNDER HYDROCHLORIDSALTET AF RILPIVIRIN, TENOFOVIR, NAVNLIG TENOFOVIRDISOPROXILFUMARAT; REG. NO/DATE: EU/1/11/737/001-002 20111128 |
| 1912999 | CA 2014 00053 | Denmark | ⤷ Sign Up | PRODUCT NAME: SIMEPREVIR ELLER ET SALT DERAF, HERUNDER SIMEPREVIRNATRIUM; REG. NO/DATE: EU/1/14/924 20140514 |
| 3533792 | CA 2021 00041 | Denmark | ⤷ Sign Up | PRODUCT NAME: APALUTAMID; REG. NO/DATE: EU/1/18/1342 20190116 |
| 2487163 | SPC/GB17/010 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; REGISTERED: UK EU/1/15/1025/001 20150715; UK EU/1/15/1025/002 20150715 |
| 2049506 | C20150046 00250 | Estonia | ⤷ Sign Up | PRODUCT NAME: KOBITSISTAAT;REG NO/DATE: EU/1/13/830/001-002 27.05.2013 |
| 0836511 | CA 2006 00019 | Denmark | ⤷ Sign Up | PRODUCT NAME: FENTANYL HYDROCHLORID |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
